NCT04673799View on ClinicalTrials.gov

Comparing of the Pharmacokinetics, Immunogenicity and Safety of MV088 and Prolia® in Healthy Adults.

PHASE1UnknownINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

October 18, 2021

Study Completion Date

October 18, 2021

Conditions
Healthy
Interventions
DRUG

MV088 injection

MV088 injection (60mg) by subcutaneous injection once on the first day

DRUG

Prolia® injection

Prolia® injection (60mg) by subcutaneous injection once on the first day

Sponsors
All Listed Sponsors
lead

Kunming Pharmaceuticals, Inc.

INDUSTRY